Medicare AdvantageCoverageMedium impact
MA11.118, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Gastroenterology, General Surgery, Oncology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA11.118 effective 10/01/2025, establishing coverage criteria for Endoscopic Submucosal Dissection (ESD) across four clinical scenarios: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy specifies detailed lesion characteristics and diagnostic requirements that must be met for coverage; claims not meeting all criteria will be denied.
Action Required
By September 15, 2025: Billing team must implement MA11.118 coverage criteria into pre-authorization workflows and billing system rules. (1) Update system to flag ESD claims (CPT 43499, 43999, 45399, 45999; HCPCS C9779) for manual review or automated validation. (2) Gastroenterology and colorectal surgery providers must document in encounter notes: lesion size, differentiation grade, ulceration status, invasion depth using specified classification systems (AJCC, JES, NICE, JNET, or Kudo), and imaging/pathology confirmation of low lymph node metastasis risk. (3) Create internal checklist or decision tree for each anatomical site (esophageal squamous cell carcinoma, esophageal adenocarcinoma/Barrett dysplasia, gastric, colorectal) with specific size thresholds (e.g., >1.5 cm for esophageal squamous cell carcinoma, >2 cm for adenocarcinoma/Barrett and colorectal). (4) Train billing and pre-auth staff on tumor invasion staging classifications. (5) Deny or request additional documentation for any ESD claim missing required criteria elements (e.g., claims for ulcerated esophageal squamous cell carcinoma lesions, gastric lesions ≥3 cm, or colorectal lesions <2 cm). Update prior authorization templates in billing software.